Relmada Therapeutics (RLMD) Cash from Operations (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Cash from Operations data on file, last reported at 15067488.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 16.6% year-over-year to 15067488.0 in Q1 2026; TTM through Mar 2026 was 42787443.0, a 24.65% increase from a year earlier, with the FY2025 full-year figure at 45786988.0, up 11.53% from the prior year.
• Cash from Operations for Q1 2026 stood at 15067488.0, down from 14596223.0 in the prior quarter.
• Over the last five years, Cash from Operations for RLMD reached as high as 6401876.0 in Q2 2025 and fell as low as 35882900.0 in Q4 2022.
• Historically, Cash from Operations has averaged 15768888.06 across 5 years, with a median of 14596223.0 in 2025.
• Across the five-year window, Cash from Operations jumped 71.44% in 2023 and slumped 65.87% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 35882900.0 in 2022, then soared by 71.44% to 10249714.0 in 2023, then advanced by 14.15% to 8799634.0 in 2024, then tumbled by 65.87% to 14596223.0 in 2025, then slipped by 3.23% to 15067488.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 15067488.0 in Q1 2026, 14596223.0 in Q4 2025, and 6721856.0 in Q3 2025.